The Efficacy and Safety of Mavacamten in Japanese Patients with Obstructive Hypertrophic Cardiomyopathy: Week 54 results from the HORIZON-HCM Study
The HORIZON-HCM study demonstrated that the safety and efficacy of the selective cardiac myosin inhibitor mavacamten observed after 30 weeks of treatment remained consistent through 54 weeks in Japanese patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), according to a study presented by Dr. Chisato Izumi, the National Cerebral and Cardiovascular Center, Japan, in the Late Breaking Clinical Trials session of the 89th Annual Scientific Meeting of the Japanese Circulation Society.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
Recommendations
